Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Acquisitions & Divestments (2018 - 2021)

Iradimed (IRMD) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $440000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 8.99% to $440000.0 in Q4 2021 year-over-year; TTM through Dec 2022 was $440000.0, a 47.85% decrease, with the full-year FY2022 number at $500000.0, down 64.03% from a year prior.
  • Change in Acquisitions & Divestments was $440000.0 for Q4 2021 at Iradimed, up from $403715.0 in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $1.5 million in Q3 2019 to a low of $400000.0 in Q2 2019.
  • A 4-year average of $825714.4 and a median of $775000.0 in 2018 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 63.56% in 2019, then tumbled 65.35% in 2020.
  • Iradimed's Change in Acquisitions & Divestments stood at $1.2 million in 2018, then decreased by 0.85% to $1.2 million in 2019, then crashed by 65.35% to $403715.0 in 2020, then grew by 8.99% to $440000.0 in 2021.
  • Per Business Quant, the three most recent readings for IRMD's Change in Acquisitions & Divestments are $440000.0 (Q4 2021), $403715.0 (Q4 2020), and $1.2 million (Q4 2019).